Partner's info collection form

Call/topic: **HORIZON-WIDERA-2025-01-ACCESS-01**

Proposal acronym: **SMART**

Contents

Administrative Info

PIC[1]**:** 999769689	**Legal Name of entity:** STAB VIDA - Investigação e Serviços em Ciências Biológicas, Lda. **Acronym of legal entity:** STAB VIDA
Country: Portugal	**Official Logo (high resolution):**

[1] A Participant Identification Code (PIC) is **a 9-digit number that serves as a unique identifier for legal entities participating in European funding programmes**. A PIC number has no expiry date. If your organization does not have a PIC, you can get it **here**.

Departments carrying out the proposed work

The information serves mainly statistical purposes. For determining the eligibility of the proposal, the official address of the organisation is taken into account.

Department 1

Department name		☒ not applicable
	☒ Same as organisation address	
Street	*Madan Parque, Rua dos Inventores, Rooms 2.18 and 2.19*	
Town	*Caparica*	
Postcode	*2825-182*	
Country	*Portugal*	

Links with other participants

Please indicate if there are dependencies with other participants of the proposal.
Two participants (legal entities) are dependent on each other where there is a controlling relationship between them:
** A legal entity is under the same direct or indirect control as another legal entity;or*
** A legal entity directly or indirectly controls another legal entity;or*
** A legal entity is directly or indirectly controlled by another legal entity.Control:*

Legal entity A controls legal entity B if:
** A, directly or indirectly, holds more than 50% of the nominal value of the issued share capital or a majority of the voting rights of the shareholders or associates of B, or*
** A, directly or indirectly, holds in fact or in law the decision-making powers in B.*

The following relationships between legal entities shall not in themselves be deemed to constitute controlling relationships:
(a) the same public investment corporation, institutional investor or venture-capital company has a direct or indirect holding of more than 50 % of the nominal value of the issued share capital or a majority of voting rights of the shareholders or associates;
(b) the legal entities concerned are owned or supervised by the same public body.

Type of link	***Participant***

*[*Same group*]* *[*Controls*]* *[*Is controlled by*]*	***N/A***

Main contact person

It is the main scientist or team leader in charge of the proposal for the participant. For participant number 1 (the coordinator), this will be the person the EU services will contact concerning this proposal (e.g. for additional information, invitation to hearings, sending of evaluation results, convocation to negotiations). The data in blue is read-only. Details (name, first name and e-mail) of Main Contact persons should be edited in Step 4 of the Submission wizard.

Title: Gender: ☐ Woman ☒ Man ☐ Non binary

First name: Orfeu Last name: Flores

E-mail: info@stabvida.com / a.orfeuflores@gmail.com

Position in org.: *Chief Executive Officer*

Department: ☒ Same as organisation

☒ Same as organisation address

Street: *Madan Parque, Rua dos Inventores, Rooms 2.18 and 2.19*

Town: Caparica Post code: 2825-182

Country: Portugal

Website: www.stabvida.com

Phone 1: +351210438606 Phone 2:

Other contact persons

First name	Last name	e-mail	Phone

Gonçalo	Doria	goncalo.doria@stabvida.com	+351210438606
Daniela	Leão	daniela.leao@stabvida.com	+351926576745
Pedro	Pinto	pedro.pinto@stabvida.com	+351926315468

Researchers involved in the proposal

Please, include also the main contact person, if a researcher									
Title	**First Name**	**Last Name**	**Gender**	**Nationality**	**E-mail**	**Career stage[2]**	**Role of researcher (in the project)**	**Reference Identifier**	**Type of identifier**
☒ Dr ☐ Mr ☐ Ms ☐ Mrs ☐ Prof	Orfeu	Flores	☐ Woman ☒Man ☐Non-binary	Portuguese	a.orfeuflores@gmail.com	☒ Cat A ☐ Cat B ☐ Cat C ☐ Cat D	☒ Leading ☐ Team member	0000-0002-6736-6598	☒ ORCID ☐ Researcher Id ☐ Other - specify
☒ Dr ☐ Mr ☐ Ms ☐ Mrs ☐ Prof	Gonçalo	Doria	☐ Woman ☒Man ☐Non-binary	Portuguese	goncalo.doria@stabvida.com	☒ Cat A ☐ Cat B ☐ Cat C ☐ Cat D	☐ Leading ☒ Team member	0000-0003-1196-983X	☒ ORCID ☐ Researcher Id ☐ Other - specify

[2] Career stages as defined in Frascati 2015 manual:
Category A – Top grade researcher: the single highest grade/post at which research is normally conducted. Example: 'Full professor' or 'Director of research'.
Category B – Senior researcher: Researchers working in positions not as senior as top position but more senior than newly qualified doctoral graduates (IsCED level 8). Examples: 'associate professor' or 'senior researcher' or 'principal investigator'.
Category C – Recognised researcher: the first grade/post into which a newly qualified doctoral graduate would normally be recruited. Examples: 'assistant professor', 'investigator' or 'post-doctoral fellow'.
Category D – First stage researcher: Either doctoral students at the IsCED level 8 who are engaged as researchers, or researchers working in posts that do not normally require a doctorate degree. Examples: 'PhD students' or 'junior researchers' (without a PhD).

Role of Participating organization in the project *(more than one options allowed)*:

Project management; ☐ Communication, dissemination and engagement; ☐ Provision of research and technology infrastructure; ☐ Co-definition of research and market needs; ☐ Civil society representative; ☐ Policy maker or regulator, incl. standardization body; ☐ Research performer; ☐ Technology developer; ☒ Testing/validation of approaches and ideas; ☒ Prototyping and demonstration; ☒ IPR management incl. technology transfer; ☐ Public procurer of results; ☐ Private buyer of results; ☐ Finance provider (public or private); ☐ Education and training; ☐ Contributions from the social sciences or/and the humanities; ☐ Other; ☐
If other, please specify: (Maximum number of characters allowed: 50)

List of up to 5 publications, datasets, software, goods, services, or any other achievements relevant to the call content.

Type of achievement	Short Description (Max 500 characters)
[Publication] **[Dataset]** **[Software]** **[Good]** **[Service]** **[Other achievement]**	***Key elements of the achievement, including a short qualitative assessment of its impact and (where available) its digital object identifier (DOI) or other type of persistent identifier (PID).*** ***Publications, in particular journal articles, are expected to be open access. Datasets are expected to be FAIR and 'as open as possible, as closed as necessary'.***
Good	*Doctor Vida is a portable, handheld device for isothermal nucleic acid amplification of pathogen's related biomarkers. It can be operated from any smartphone in a clinical or research setting, but also at home, at the office, etc. The validated sample types include nasal, nasopharyngeal, oral, vaginal or anal swabs, faeces or urine samples. It allows to get from sample collection to results within 30-*

	50min., with only 5minutes hands-on.
Software	*Dr Vida Pocket PCR mobile app* *Available in* *iOS - https://apps.apple.com/pt/app/dr-vida-pocket-pcr/id1522700987* *Android - https://play.google.com/store/apps/details?id=com.stabvida.dvpocket* *It is designed for in vitro diagnostics, serving as a companion to the Doctor Vida pocket device. Health professionals can control the device via Bluetooth, managing assays, monitoring progress, and accessing historical data and account settings through the mobile app.*
Publication	*Patent WO2021220192* *Method and portable device for detection of nucleic sequences in suspected coronavirus samples.* *The present invention refers to a method and a portable device for the detection and identification of specific nucleic acids sequences in different types of samples, by means of an optimised reverse transcriptase technique and/or isothermal amplification, usinq specific oliqonucleotide primers of the tarqet region(s) to detect.* *Inventors: Orfeu Flores & Gonçalo Doria*
Publication	*G Doria et al (2022) An isothermal lab-on-phone test for easy molecular diagnosis of SARS-CoV-2 near patients and in less than 1 hour. Int J Infect Dis, 123:1-8. doi: 10.1016/j.ijid.2022.07.042* *Study on DoctorVida pocket SARS-CoV-2 assay highlights excellent performance with direct nasopharyngeal crude samples. It offers a low-cost, real-time, rapid, and accurate identification of SARS-CoV-2 infections at the point of care, facilitating clinical management and population screening.*
Publication	*Patent EP14736473 (granted)* *Biochip, antigen bouquet, optical reader and method for detecting and monitoring diseases.* *The present invention relates to a biochip comprising an antigen bouquet, to be inserted into an optical reader and relates to a method for detecting and monitoring antibodies associated with the presence of diseases in biological samples, using such biochip and such optical reader.*

List of up to 5 most relevant previous projects or activities, connected to the subject of this proposal

Name of the project or activity	Short Description (Max 500 characters)
DV4COVID19 (P2020 - LISBOA-01-02B7-FEDER-050356)	*"DV4COVID19 - Combating COVID19 with rapid point-of-care diagnostic tests": Develoment of a medical device for diagnosing COVID-19 in vitro (DIV). The diagnosis is unique by being fast (20 minutes) and being able to be carried out in a relocated way from any laboratory (point of care diagnosis). This device, called Doctor Vida, results from previous research*

	projects and was initially conceived for the diagnosis of infectious diseases, namely Lyme disease.
Spinit-crispr (P2020 - POCI-01-0247-FEDER-033778)	*"Spinit-crispr: Specific detection of nucleic acids for point-of-care diagnosis of tropical diseases": On a co-promotion initiative, the project presents the development of a rapid diagnostic test panel of Dengue, Zika and Chikungunya febrile syndromes. The grant supports all R&D developments and the translation of multiplexed molecular isothermal amplification techniques to a lab-on-a-disc device and subsequent analytical and clinical validation.*
MEDSECURANCE (HORIZON – ID 101095448)	*"Advanced Security-for-safety Assurance for Medical Device IoT": this project will develop new methodologies, infrastructures and technologies that enable the effective, harmonious development and evolution of a secure Internet of Medical Things. The project will design a scalable and verifiable security system-engineering solution co-developed and validated with medical industry partners and accompanied by proposed EU guidelines for increased assurance of connected health devices.*
LungCARD_RISE (H2020 – ID 734790)	*LungCARD_RISE "Blood test for clinical therapy guidance of non-small cell lung cancer patients": NSCLC patient's blood sample is loaded into the LungCARD chip which is processed in an automatic instrument. Then, the outcoming PCR products are analysed by NGS following the supplied LungCARD NGS protocol and the results are analysed by the provided bioinformatics software, which automatically delivers report of the companion diagnostic (CDx) ready for medical interpretation.*
HILYSENS_II (H2020 – ID 606348)	*"Demonstration Activities for the clinical validation of the prototype HILYSENS Lab-on-a-Chip": project aimed to showcase the diagnostic prototype HILYSENS Lab-on-a-Chip for Lyme disease. The biochip detected Borrelia in patients along with a portable reader, addressing the sensitivity gap in current methods. It included SMEs from Portugal, Italy, and Spain to achieve clinical validation, regulatory approval in Europe and the US, meeting the urgent need for enhanced Lyme disease diagnostics.*

Description of any significant infrastructure and/or any major items of technical equipment, relevant to the proposed work

Name of infrastructure or equipment	Short Description (Max 300 characters)
Service labs (ISO9001 certified)	*Our ISO 9001 certified service laboratories offer a suite of cutting-edge genomics and antibody services, including Sanger sequencing, NGS, bioinformatics, and antibody development and production, providing comprehensive solutions for advanced genomics and protein-related research.*
Medical device factory	*Our ISO 13485 compliant medical device manufacturing setup*

(ISO 13485 compliant)	*facilitates production of our Doctor Vida pocket products. This encompasses the manufacturing of assay reagents, hardware, electronics, and quality control processes, ensuring adherence to rigorous standards in the medical device industry.*
R&D laboratory	*Our cutting-edge R&D lab is equipped with advanced tools for molecular diagnostics, in vitro devices and 3D prototyping development. Moreover, the R&D facility integrates also software development capabilities to support comprehensive innovation in the creation of cutting-edge medical technologies.*

Gender Equality Plan

Does the organization have a Gender Equality Plan (GEP) covering the elements listed below?

No

Minimum process-related requirements (building blocks) for a GEP

- **Publication:** formal document published on the institution's website and signed by the top management
- **Dedicated resources:** commitment of human resources and gender expertise to implement it.
- **Data collection and monitoring:** sex/gender disaggregated data on personnel (and students for establishments concerned) and annual reporting based on indicators.
- **Training:** Awareness raising/trainings on gender equality and unconscious gender biases for staff and decision-makers.
- Content-wise, recommended areas to be covered and addressed via concrete measures and targets are:

♦ **work-life balance and organisational culture;**
♦ **gender balance in leadership and decision-making;**
♦ **gender equality in recruitment and career progression;**
♦ **integration of the gender dimension into research and teaching content;**
♦ **measures against gender-based violence including sexual harassment.**

Involved Third Parties

Does the participant plan to subcontract[3] certain tasks (please note that core tasks of the project should not be sub-contracted)	**N**
If **yes**, please describe and justify the tasks to be subcontracted.	
Does the participant envisage that part of its work is performed by Affiliated	**N**

[3] Subcontractors may participate in the action, if necessary for the implementation. Subcontractors must implement their action tasks in accordance with Article 11. The costs for the subcontracted tasks (invoiced price from the subcontractor) are eligible and may be charged by the beneficiaries, under the conditions set out in Article 6. The costs will be included in Annex 2 as part of the beneficiaries' costs.

Entities[4] (Article 8 of the Corporate Model Grant Agreement)	
If **yes**, please describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party.	
Does the participant envisage the use of contributions in kind provided by third parties[5] (Articles 9.2 of the Corporate Model Grant Agreement)	**N**
If **yes**, please describe the third party(ies) and its/ their contribution(s).	
Does the participant envisage that part of the work is performed by Associated partners[6] (Article 9.1 of the Corporate Model Grant Agreement)?	**N**
If **yes**, please describe the Associated Partner(s) and their contributions	
Does the participant envisage that part of the work is performed by international organisations[7] (Article 10.2 of the Corporate Model Grant Agreement)?	**N**
If **yes**, please describe the International Partner(s) and their contributions	

[4] Affiliated entities can charge costs and contributions to the action under the same conditions as the beneficiaries and must implement the action tasks attributed to them in Annex 1 in accordance with Article 11. Their costs and contributions will be included in Annex 2 and will be taken into account for the calculation of the grant. The beneficiaries must ensure that all their obligations under this Agreement also apply to their affiliated entities. The beneficiaries must ensure that the bodies mentioned in Article 25 (e.g. granting authority, OLAF, Court of Auditors (ECA), etc.) can exercise their rights also towards the affiliated entities. Breaches by affiliated entities will be handled in the same manner as breaches by beneficiaries. Recovery of undue amounts will be handled through the beneficiaries. If the granting authority requires joint and several liability of affiliated entities (see Data Sheet, Point 4.4), they must sign the declaration set out in Annex 3a and may be held liable in case of enforced recoveries against their beneficiaries (see Article 22.2 and 22.4).

[5] Other third parties may give in-kind contributions to the action (i.e. personnel, equipment, other goods, works and services, etc. which are free-of-charge), if necessary for the implementation. Third parties giving in-kind contributions do not implement any action tasks. They may not charge costs or contributions to the action and the costs for the in-kind contributions are not eligible.

[6] Associated partners must implement the action tasks attributed to them in Annex 1 in accordance with Article 11. They may not charge costs or contributions to the action and the costs for their tasks are not eligible.

[7] Participants which are established in a non-EU country